Susquehanna International Group
IMUC

Susquehanna International Group’s ImmunoCellular Therapeutics, Ltd. IMUC Stock Holding History

Susquehanna International Group’s Portfolio IMUC Stock Details IMUC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q2 		– Sell
-9,210
Closed -$449K – 10529
2014
Q1 		$449K Sell
9,210
-858
-9% -$42K ﹤0.01% 6912
2013
Q4 		$372K Buy
10,068
+5,673
+129% +$537K ﹤0.01% 7230
2013
Q3 		$452K Sell
4,395
-105
-2% -$11.5K ﹤0.01% 6583
2013
Q2 		$349K Buy
+4,500
New +$431K ﹤0.01% 6576

Other funds holding IMUC

WS
Wedbush Securities Los Angeles, California $3.88B AUM 32.38% 1-Year Est. Return

Susquehanna International Group's IMUC Position: Q4 2018 in Review

Susquehanna International Group sold out of ImmunoCellular Therapeutics, Ltd. (IMUC) in Q4 2018, closing a stake of 32,871 shares — an estimated $7K sold.

Susquehanna International Group first reported a position in IMUC in Q2 2013 and held it in 11 quarters. The position peaked at $962K in Q1 2015. 3 funds tracked by Wall St. Rank hold IMUC as of Q4 2018.

  • Susquehanna International Group reported no remaining ImmunoCellular Therapeutics, Ltd. position as of Q4 2018 after selling out during the quarter.
  • Susquehanna International Group sold 32,871 ImmunoCellular Therapeutics, Ltd. shares in Q4 2018, an estimated $7K.
  • Susquehanna International Group first reported a position in ImmunoCellular Therapeutics, Ltd. in Q2 2013 and held it in 11 quarters.
  • Susquehanna International Group's ImmunoCellular Therapeutics, Ltd. position peaked at $962K in Q1 2015.
  • 3 funds tracked by Wall St. Rank held ImmunoCellular Therapeutics, Ltd. as of Q4 2018.

Based on Susquehanna International Group's 13F filing for Q4 2018, filed 14 Feb 2019.